Guardant Health and Quest Collaborate on Colon Cancer Screening Test

Summary

Guardant Health and Quest Diagnostics have announced a strategic collaboration to enhance access to Guardant’s Shield™ blood-based colorectal cancer screening test in the U.S. This partnership allows Quest’s provider clients to order Shield directly through their existing accounts, facilitating patient referrals to Quest’s service centers for blood draws. Shield, the first FDA-approved blood test for colorectal cancer screening in average-risk adults aged 45 and older, aims to improve early detection and patient outcomes. The test is expected to be available for orders through Quest in early 2026.StockTitan

Impact Analysis

So basically, Guardant Health is leveraging Quest Diagnostics’ extensive network to significantly broaden the reach of its Shield™ blood-based colorectal cancer screening test. The timing is interesting, given the recent positive results of the Shield V2 algorithm and the FDA approval, which positions Guardant to capitalize on the growing demand for non-invasive cancer diagnostics. The collaboration with Quest, a major player in diagnostic services, should streamline the ordering and referral process, making it easier for providers to adopt this new screening method. This move could potentially drive significant revenue growth for Guardant by tapping into Quest’s large provider base and patient network. However, the market might be underestimating the execution risks and the time it will take to fully integrate and scale this offering. Watch for updates on the rollout progress and any early adoption metrics. Overall, this partnership could be a game-changer in the colorectal cancer screening market, but the real impact will depend on execution and market uptake.StockTitan+ 3